Shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have earned an average broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have given a strong buy rating to the company. Adamis Pharmaceuticals Corporation’s rating score has declined by 33% in the last 90 days as a result of a number of analysts’ ratings changes.

Analysts have set a 12-month consensus price objective of $9.83 for the company and are anticipating that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Adamis Pharmaceuticals Corporation an industry rank of 97 out of 265 based on the ratings given to related companies.

Several equities research analysts have recently issued reports on ADMP shares. Raymond James Financial, Inc. started coverage on shares of Adamis Pharmaceuticals Corporation in a research report on Tuesday, September 12th. They set an “outperform” rating and a $7.00 price objective on the stock. Maxim Group reiterated a “buy” rating and set a $13.00 price objective on shares of Adamis Pharmaceuticals Corporation in a research report on Monday, August 21st. B. Riley reiterated a “buy” rating and set a $9.50 price objective on shares of Adamis Pharmaceuticals Corporation in a research report on Wednesday, October 4th. Finally, ValuEngine cut shares of Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.

Shares of Adamis Pharmaceuticals Corporation (ADMP) opened at $4.55 on Tuesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.19 and a quick ratio of 2.04. Adamis Pharmaceuticals Corporation has a one year low of $2.55 and a one year high of $6.45.

Institutional investors have recently added to or reduced their stakes in the company. First Allied Advisory Services Inc. purchased a new position in shares of Adamis Pharmaceuticals Corporation in the second quarter valued at $114,000. Bank of New York Mellon Corp grew its holdings in shares of Adamis Pharmaceuticals Corporation by 131.0% in the third quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 15,577 shares in the last quarter. Stonebridge Capital Advisors LLC grew its holdings in shares of Adamis Pharmaceuticals Corporation by 22.2% in the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 5,000 shares in the last quarter. Wells Fargo & Company MN purchased a new position in shares of Adamis Pharmaceuticals Corporation in the second quarter valued at $169,000. Finally, IFP Advisors Inc grew its holdings in shares of Adamis Pharmaceuticals Corporation by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock valued at $179,000 after purchasing an additional 32,965 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/14/adamis-pharmaceuticals-corporation-admp-given-9-83-average-target-price-by-brokerages.html.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals Corporation (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.